Treatment of neurodegenerative diseases with neural cell transplantation

Expert Opinion on Investigational Drugs

Volumn 7, Issue 4, 1998, Pages 527-534

  Dinsmore, Jonathan h ^a  

^a GENVEC INC   (United States)

Author keywords

cell transplantation; central nervous system; neurodegenerative disease

Indexed keywords

EID: 33645715877     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.7.4.527     Document Type: Review

References (66)

1. DUNNETT SB: Functional repair of striatal systems by neural transplants: evidence for circuit reconstruc-tion. Behaviour. Brain Res. (1995) 66 (1-2): 133 – 142.
2. FREED WJ: Neural transplantation: prospects for clini-cal use. Cell Transplant. (1993) 2: 13 – 31.
3. BJORKLUND A: Neural transplantation - an experimen-tal tool with clinical possibilities. Trends Neurosci. (1991) 14 (8): 319 – 322.
4. GAGE FH, FISHER LJ: Intracerebral grafting: a tool for the neurobiologist. Neuron (1991) 6: 1 – 12.
5. OLANOW CW, KORDOWER JH, FREEMAN TB: Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci. (1996) 19: 102 – 109.
6. KORDOWER JH et al.: Dopaminergic transplants in pa-tients with Parkinson's disease: neuroanatomical cor-relates of clinical recovery. Exp. Neurol. (1997) 144: 41 – 46.
7. DEACON TW et al.: Cytoarchitectonic development, axon-glia relationships, and long distance axon growth of porcine striatal xenografts in rats. Exp. Neu-rol. (1994) 130 (0: 151 – 67.
8. JACOBY DB et al: Fetal pig neural cells as a restorative therapy for neurodegenerative disease. Artificial Or-gans (1997) 21 (10: 1192 – 1198.
9. PAKZABAN P et al: A novel mode of immunoprotection of neural xenotransplants: masking of donor major histocompatibility complex class I enhances trans-plant survival in the central nervous system. Neurosci-ence (1995) 65: 983 – 996.
10. WIDNER H, REHNCRONA S: Transplantation and surgi- cal treatment of Parkinsonian syndromes. Curr. Opin. Neurol Neurosurg. 1993. 6 (3): 344 – 349.
11. WICTORIN K: Anatomy and connectivity of intrastriatal striatal transplants. Prog. Neurobiol. (1992) 38: 611 – 639.
12. WICTORIN K, OUIMET CC, BJORKLUND A: Intrinsic or-ganization and connectivity of intrastriatal striatal transplants in rats as revealed by DARPP-32 immuno-histochemistry: specificity of connections with the le-sioned host brain. Eur. j Neurosci. (1989) 1: 690 – 701.
13. ZOMPA EA et al: Transplant therapy: recovery of func-tion after spinal cord injury. J. Neurotrauma (1997) 14 (8): 479 – 506.
14. BAREN-VAN EVERCOOREN A: Future prospects in trans-plantation. Ann. Neurol (1994) 36: S151–S156.
15. DEACON T et al.: Histological evidence of foetal pig neu-ral cell survival after transplantation into a patient with Parkinson's disease. Nature. Med. (1997) 3: 350 – 353.
16. FREEMAN TB et al.: Bilateral foetal nigral transplanta-tion into the postcommissural putamen in Parkin-son's disease. Ann. Neurol. (1995) 38 (3): 379 – 388.
17. KORDOWER JH et al.: Functional foetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ul-trastructural, and metabolic studies. J. Comp. Neurol (1996) 370: 203 – 230.
18. KORDOWER JH et al.: Neuropathological evidence of graft survival and striatal reinnervation after the trans-plantation of foetal mesencephalic tissue in a patient with Parkinson's disease [see comments]. New Engl. J. Merl. (1995) 332 (17): 1118 – 1124.
19. DINSMORE JH: Immunoprivileged sites for allo- and xe-notransplantation. In: Xenotransplantation. Cooper DKC et al. (Eds.), Springer-Verlag, New York, USA (1996): 199 – 205.
20. HUFFAKER TK et al.: Xenografting of foetal pig ventralmesencephalon corrects motor asymmetry in the rat model of Parkinson's disease. Exp. Brain Res. (1989) 77: 329 – 336.
21. HANTRAYE P et al.: Intrastriatal transplantation of cross-species foetal striatal cells reduces abnormal movements in a primate model of Huntington's dis-ease. Proc. Natl. Acad. Sci. USA (1992) 89 (9): 4187 – 4191.
22. GALPERN WR et al.: Xenotransplantation of porcine foetal ventral mesencephalon in a rat model of Parkin-son's disease: functional recovery and graft morphol-ogy. Exp. Neurol. (1996) 140: 1 – 13.
23. FREEMAN TB et al.: Cross-species intracerebral grafting of embryonic swine dopaminergic neurons. Prog. Brain Res. (1988) 78: 473 – 477.
24. STRECKER RE etal.: Autoregulation of dopamine release and metabolism by intrastriatal nigral grafts as re-vealed by intracerebral dialysis. Neuroscience (1987) 22: 169 – 178.
25. GRASBON-FRODL EM et al.: Phenotypic development ofthe human embryonic striatal primordium: a study of the cultured and grafted neurons from the lateral and medial ganglionic eminences. Neuroscience (1996) 73: 171 – 183.
26. BRUNDIN P, FRICKER RA, NAKAO N: Paucity of P-zonesin striatal grafts prohibit commencement of clinical trials in Huntington's disease. Neuroscience (1996) 71: 895 – 897.
27. NAIMI S et al.: Ontogeny of human striatal DARPP-32 neurons in fetuses and following xenografting to the adult brain. Exp. Neurol (1996) 137: 15 – 25.
28. AEBISCHER P et al.: Encapsulation of neurotrophic factor-releasing cells for the treatment of neurodegen-erative diseases. Restorat. Neurol. Neurosci. (1995) 8 (1-2): 65 – 66.
29. SAGOT Y et al.: Polymer encapsulated cell lines geneti-cally engineered to release ciliary neurotrophic factor can slow down progressive motor neuronopathy in the mouse. Europ. j Neurosci. (1995) 7 (6): 1313 – 1322.
30. NAKAHARA Y, GAGE FH, TUSZYNSKI MH: Grafts of fi-broblasts genetically modified to secrete NGF, BDNF, NT-3, or basic FGF elicit differential responses in the adult spinal cord. Cell Transplant. (1996) 5 (2): 191 – 204.
31. LINDNER MD et al. Implantation of encapsulated rate-cholamine and GDNF-producing cells in rats with uni-lateral dopamine depletions and parkinsonian symptoms. Exp. Neurol. (1995) 132 (0: 62 – 76.
32. KORDOWER JH et al.: Intrastriatal implants of polymer encapsulated cells genetically modified to secrete hu-man nerve growth factor - trophic effects upon © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(4) cholinergic and noncholinergic striatal neurons. Neu-roscience (1996) 72 (1): 63 – 77.
33. HAMMANG JP et al.: Delivery of neurotrophic factors tothe CNS using encapsulated cells - developing treat-ments for neurodegenerative diseases. Cell Transplant. (1995) 4 (Suppl 1): S27–S28.
34. FRIM DM et al.: Implanted fibroblasts genetically engi-neered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to do-paminergic neurons in the rat. Proc. Natl. Acad. ScL USA (1994) 91 (10: 5104 – 5108.
35. EMERICH DF et al.: Protective effect of encapsulatedcells producing neurotrophic factor cntf in a monkey model of Huntington's disease. Nature (1997) 386(6623) 395 – 399.
36. EMERICH DF et al: Cellular delivery of human CNTFprevents motor and cognitive dysfunction in a rodent model of Huntington's disease. Cell Transplant. (1997) 6(3) 249 – 266.
37. EMERICH DF et al. Implants of encapsulated human cntf-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease. J. Neurosci. (1996) 16 (16) 5168 – 5181
38. EMERICH DF et al. Alleviation of behavioral deficits in aged rodents following implantation of encapsulated GDNF-producing fibroblasts. Brain Res. (1996) 736 (1-2): 99 – 110.
39. EMERICH DF et al. Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate - rescue and sprouting of degenerating cholinergic ba-sal forebrain neurons. J. ComparaL Neurol (1994) 349 (1) 148 – 164
40. CALNE DB: Treatment of Parkinson's disease. New Engl J. Med. (1993) 29: 1021 – 1027.
41. TSUI JKC: Treatment of Parkinson's disease. In: Neuro-degenerative Diseases. Caine DB (Ed.), WB Saunders, Phila-delphia,USA (1994): 573 – 582.
42. STEECE-COLLIER K et al.: Chronic levodopa impairsmorphological development of grafted embryonic do-pamine neurons. Exp. Neurol. (1990) 110: 201 – 208.
43. WALKINSHAW G, WATERS CM: Induction of apoptosisin catecholaminergic PC12 cells by L-DOPA: implica-tions for the treatment of Parkinson's disease. J. Clin. Invest. (1995) 95: 2458 – 2464.
44. SUBRAMANIAN T et al. Polymer-encapsulated PC-12 cells demonstrate high-affinity uptake of dopamine in vitro and F-18-DOPA uptake and metabolism after in-tracerebral implantation in nonhuman primates. Cell Transplant (1997) 6 (5): 469 – 477.
45. EMERICH DF et al. Implantation of polymer- encapsulated human nerve growth factor-secreting fi-broblasts attenuates the behavioral and neuropa-thological consequences of quinolinic acid injections into rodent striatum. Exp. Neurol. (1994) 130 (1): 141 – 150.
46. YAN Q, ELLIOTT J, SNIDER WD: Brain-derived neuro-trophic factor rescues spinal motor neurons from axotomy-induced cell death. Nature (1 9 9 2) 360(6400753 – 755.
47. YAN Q, MATHESON C, LOPEZ OT: In vivo neurotrophic effects of GDNF on neonatal and adult facial motor neurons [see comments]. Nature (1995) 373 (6512): 341 – 344.
48. TOMOZAW Y, APPEL SH: Soluble striatal extracts en-hance development of mesencephalic dopaminergic neurons in vitro. Brain Res. (1986) 399: 111 – 124.
49. SCHNELL L et al.: Neurotrophin-3 enhances sprouting of corticospinal tract during development and after adult spinal cord lesion. Nature (1994) 367: 170 – 173.
50. LINDSAY RM et al: Neurotrophic factors: from mole-cule to man. Trends Neurosci. (1994) 17: 182 – 190.
51. LIN LF et al.: GDNF: a glial cell line-derived neuro-trophic factor for midbrain dopaminergic neurons [see comments]. Science (1993) 260 (5110: 1130 – 1132.
52. IP NY et al.: CNTF FGF and NGF collaborate to drive the terminal differentiation of MAH cells into postmitotic neurons. Neuron (1994) 13: 443 – 455.
53. BANG AG, GOULDING MD: Regulation of vertebrate neural cell fate by transcription factors. Curr. Opin. Neurobiol (1996) 6: 25 – 32.
54. AHMED S, REYNOLDS BA, WEISS S: BDNF enhances the differentiation but not the survival of CNS stem cell-derived neuronal precursors. J. Neurosci. (1995) 15(8) 5765 – 5778.
55. SAPORTA S et al.: Microcarrier enhanced survival of hu-man and rat foetal ventral mesencephalon cells im-planted in the rat striatum. Cell Transplant. (1997) 6: 579 – 584.
56. MCKAY R: Stem cells in the central nervous system. Sci-ence (1997) 276: 66 – 71.
57. JOHE KK et al.: Single factors direct the differentiation of stem cells from the foetal and adult central nervous system. Genes Develop. (1996) 10: 3129 – 3140.
58. KLEPPNER SR et al.: Transplanted human neurons de- rived from a teratocarcinoma cell line (NTera-2) ma-ture, integrate, and survive for over 1 year in the nude mouse brain. J. Comp. Neurol. (1995) 357:618-632. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(4)
59. KORDOWER JH et al.: Grafts of EGF-responsive neural stem cells derived from GFAP-HNGF transgenic mice - trophic and tropic effects in a rodent model of Huntington's disease. J. Comparat. Neurof (1997) 387 (1): 96 – 113.
60. REYNOLDS BA, TETZLAFF W, WEISS S: A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes. J. Neurosci. (1992) 12 (104565 – 4574.
61. SNYDER EY et al.: Multipotent neural cell lines can en-graft and participate in development of mouse cere-bellum. Cell (1992) 68: 33 – 51.
62. SNYDER EY, TAYLOR RM, WOLFE JH: Neural progenitor cell engraftment corrects lysosomal storage through-out the MPS VII mouse brain. Nature (1995) 374(6520) 367 – 370.
63. TROJANOWSKI JQ et al.: In vivo and in vitro models of medulloblastomas and other primitive neuroectoder-mal brain tumors of childhood. Mol. Chem. Neuropathol. (1994) 21 (2-0: 219 – 239.
64. WHITTEMORE SR, SNYDER EY: Physiological relevance and functional potential of central nervous system-derived cell lines. Mol. Neurobiol (1996) 12 (0: 13 – 38.
65. PLEASURE SJ, LEE VM: NTera 2 cells: a human cell line which displays characteristics expected of a human committed neuronal progenitor cell. J. Neurosci. Res. (1993) 35 (0: 585 – 602.
66. SINDEN JD et al.: Recovery of spatial learning by grafts of a conditionally immortalized hippocampal neu-roepithelial cell line into the ischaemia-lesioned hip-pocampus. Neuroscience (1997) 81: 599 – 608.